Results 151 to 160 of about 31,287 (200)
Some of the next articles are maybe not open access.
Hydroxyurea derivatives—1-methyl-1-hydroxyurea and 1-ethyl-1-hydroxyurea
Biochemical Pharmacology, 1968Abstract Certain aspects of the biochemical pharmacology of 1-methyl-1-hydroxyurea (MHU) and 1-ethyl-1-hydroxyurea (EHU) were investigated and were contrasted with the actions of hydroxyurea (HU). Assay of inhibitory action against DNA synthesis in an ascites tumor cell system in vitro revealed an order of relative potentcy of MHU > HU > EHU ...
openaire +2 more sources
Advances in the use of hydroxyurea
Hematology, 2009Abstract Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD.
Russell E, Ware, Banu, Aygun
openaire +2 more sources
Pharmacokinetics and Pharmacodynamics of Hydroxyurea
Clinical Pharmacokinetics, 1998Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms.
P R, Gwilt, W G, Tracewell
openaire +2 more sources
Hydroxyurea: Mechanism of Action
Science, 1963Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy. This suggests that the drug is hydrolyzed yielding hyroxylamine, which then cleaves thioesters, in particular acetyl-coenzyme A.
W N, FISHBEIN, P P, CARBONE
openaire +2 more sources
Hydroxyurea Administered Intermittently
JAMA: The Journal of the American Medical Association, 1965THE SYNTHESIS of hydroxyurea (Hydrea) was reported in 1869 by Dresler and Stein. 1 In animal studies, Rosenthal et al 2 found that the compound produced anemia, severe leukopenia, and megaloblastic changes in the peripheral blood and bone marrow. Recently, this compound has been introduced into cancer chemotherapy. Tumor responses have been observed in
H J, LERNER, G L, BECKLOFF
openaire +2 more sources
Inhibition of urease by hydroxyurea
Biochemical Pharmacology, 1965Abstract Hydroxyurea was shown to be a potent inhibitor of urease; 50% inhibition occurred at a concentration of approximately 5 × 10−5 M. Preincubation of the enzyme with the inhibitor prior to addition of substrate yielded inhibition which progressed with time, whereas simultaneous addition of inhibitor and substrate to the enzyme reduced the ...
openaire +2 more sources
Medical Journal of Australia, 1980
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire +2 more sources
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire +2 more sources
Hydroxyurea and Bronchogenic Carcinoma
Australasian Radiology, 1974SUMMARYThe disappointing outlook in the treatment and prognosis of lung cancer still continues and is an enigma which baffles clinicians in the management of this disease.A selected clinical trial was carried out in the Royal Adelaide Hospital using hydroxyurea and irradiation in one group of patients versus a placebo group who received irradiation ...
openaire +2 more sources
Excretion of hydroxyurea into milk
Cancer, 1987This article documents that hydroxyurea (HUR) is excreted into human breast milk, and it reviews the literature describing similar evaluations for other antineoplastic agents.
R K, Sylvester +4 more
openaire +2 more sources